您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版)

• 论文 • 上一篇    下一篇

47例HBeAg阴性慢性乙型肝炎拉米夫定停药后疗效持久性研究

李晓迎,王磊,刘峰   

  1. 山东大学医学院济南市传染病医院, 山东 济南 250021
  • 收稿日期:2006-12-10 修回日期:1900-01-01 出版日期:2007-09-24 发布日期:2007-09-24
  • 通讯作者: 王磊

Durability of the effects after cessation of lamivudine for 47 patients with HBeAg-negative chronic hepatitis B

LI Xiao-ying, WANG Lei, LIU Feng   

  1. Jinan Infectious Disease Hospital, School of Medicine, Shandong University,Jinan 250021, Shandong, China
  • Received:2006-12-10 Revised:1900-01-01 Online:2007-09-24 Published:2007-09-24
  • Contact: WANG Lei

摘要: 研究HBeAg阴性慢性乙型肝炎(HBeAg阴性慢乙肝)停药后拉米夫定疗效的持久性及影响因素。方法:对47例使用拉米夫定总疗程≥24月、HBV-DNA阴转达18个月以上HBeAg阴性慢乙肝,分别于停药后进行肝脏生化学、HBV-DNA检测和随访观察。结果:停药后3、6、12、24和36个月累计复发率分别为25.5%、25.5%、41.8%、48.3%和54.8%。复发23例,在4、9和12个月的复发累计病例分别占复发病例的52.2%、65.2%和82.6%,复发最长的1例为39个月。停药时的年龄与拉米夫定停药后疗效持久性有关。结论:HBeAg阴性慢乙肝拉米夫定停药后疗效持久性较HBeAg阳性低,年龄轻者复发率低。

Abstract: Objective: To investigate the durability of the effects after cessation of lamivudine for HBeAg-negative chronic hepatitis B(CHB) patients. Methods: Forty-seven patients subjecting to lamivudine for no less than 24 months and their HBVDNA-negative duration more than 18 months were enrolled in this study. Hepatic biochemical parameters, HBV-DNA determination, and follow-up were determined after cessation of lamivudine. Results: The cumulative rate of relapse after 3, 6, 12, 24 and 36 months after cessation of lamivudine was 25.5%, 25.5%, 41.8%, 48.3% and 54.8%, respectively. Twenty-three patients relapsed and the latest happened on the 39th month. The cumulative relapse ratio at month 4, 9 and 12 was 52.2%. 65.2% and 82.6%, respectively. The durability of the effects after cessation of lamivudine was related to age at the end of treatment. Conclusion: Durability of the effects after cessation of lamivudine of HBeAg-negative patients is lower than that of HBeAg-positive ones. The younger the patient is, the lower the relapse rate.

Key words: Chronic hepatitis B, Lamivudine, Durability, Effectiveness

中图分类号: 

  • R575.1
[1] 王胜江1,徐成伟2. 慢性肝病患者血浆中凝血酶激活的纤溶抑制物(TAFI)水平与慢性肝损伤的相关性[J]. 山东大学学报(医学版), 2012, 50(4): 83-.
[2] 许伟华1, Tobias A Beyer2, 杨法林3,王洪波1. 胆总管结扎所致肝损伤中Nrf2对细胞信号传导和基因表达的影响[J]. 山东大学学报(医学版), 2010, 48(10): 39-.
[3] 邵洛林,许伟华,周成军,王洪波,郭建强. Nrf2在小鼠非酒精性脂肪性肝病发病机制中的作用[J]. 山东大学学报(医学版), 2010, 48(3): 53-56.
[4] . 羟基红花黄色素A对四氯化碳急性肝损伤的保护作用[J]. 山东大学学报(医学版), 2009, 47(8): 67-71.
[5] 欧阳福生. 老年病毒性肝炎267例临床报告[J]. 山东大学学报(医学版), 2014, 52(S1): 83-84.
[6] 杨沛华, 谢永忠, 夏金荣, 杜传策, 包月妃, 周观林, 王利勤. 非免疫清除期乙型肝炎患者行肾结石手术后HBV-LP、HBV-M及HBV-DNA变化研究[J]. 山东大学学报(医学版), 2014, 52(S1): 104-105.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!